Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grass Pollen Sublingual Tablet Immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Moderate to Severe Seasonal Allergic Rhinitis
2018-003456-20Phase 2Unknown
- Sponsor
- Division of Allergy, Immunology, and Transplantation
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of phleum pratense allergen extract and dupilumab in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Division of Allergy, Immunology, and Transplantation. Primary endpoint: NAC TNSS AUC0-1hr. Status: unknown.
02
Drugs
phleum pratense allergen extractdupilumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2018-003456-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003456-20.